UnitedHealth Group (NYSE: UNH) had one of the worst eighteen months any blue-chip stock has seen in years. Down more than 50% from its all-time high. CEO Andrew Witty stepping down in May citing personal reasons after less than three years in the role. A criminal DOJ probe that is still open today with no timeline. And then — April happened.

The stock climbed 37% in a single month. Goldman Sachs added it to their U.S. Conviction List on May 1 with a $435 price target. Bank of America, JPMorgan, and Raymond James all raised their targets within two weeks of Q1 earnings. Institutional money started moving back in.

The part people skip: none of the problems that caused the selloff are fully resolved. That tension is exactly what makes this interesting right now.

On April 21, UNH reported Q1 2026 results. Revenue hit $111.7 billion, up 2% year-over-year. Adjusted EPS came in at $7.23 versus a consensus estimate of $6.61 — that’s a meaningful beat. Adjusted EBIT cleared estimates by roughly $790 million. Cash flow from operations landed at $8.9 billion, or about 1.4x net income. Management raised full-year 2026 adjusted earnings guidance to greater than $18.25 per share.

The number that actually moved the stock: the medical care ratio came in at 83.9%, down 90 basis points year-over-year.

That ratio was the single metric that crushed UNH through most of 2025. When it rises, the company is paying out more in claims relative to premiums — margin compression in the most direct sense. When it falls, the direction of the entire recovery thesis changes. Ninety basis points of improvement in one quarter got people’s attention for good reason. It doesn’t mean the cycle is over. But it does suggest the worst of the Medicare Advantage cost surge may be behind them.

A quick note on what changed structurally — and this part tends to get overlooked. UNH made a deliberate, painful call: they exited Medicare Advantage markets across 109 counties in 16 states that weren’t generating acceptable returns. Fewer members. Tighter geography. UnitedHealthcare CEO Tim Noel was direct on the Q1 call — 2026 is explicitly prioritizing margin recovery over membership growth. That’s a real strategic shift, not PR language. The other piece: CMS finalized 2027 Medicare Advantage payment rates significantly above what was initially proposed earlier this year. The original near-flat proposal sent the stock down nearly 20% in January. The finalized rates removed one of the more significant overhangs on the managed care group broadly.

Analyst targets, for reference:

• Goldman Sachs — Buy | $435 PT (Conviction List, May 1; raised from $400 on April 22)
• Bank of America — Buy | $420 PT (raised from $380 on May 13)
• JPMorgan — Overweight | $420 PT (raised from $389 on April 28)
• Raymond James — Outperform | $370 PT (raised from $330 on April 21)

Worth noting that Goldman’s framing was specifically that the recovery is still in its early stages. Which is bullish — but also means the sharp April move may have already captured a chunk of the near-term opportunity.

Here’s where I’m at on the AI story, because it’s genuinely underappreciated. UNH budgeted $1.5 billion in AI and technology spending for 2026. The operating cost ratio rose to 13.8% from 12.4% last year — a chunk of that increase is the cost of building the infrastructure. Management says they’re targeting nearly $1 billion in operating cost reductions this year as the AI spend starts generating returns. Over 80% of member calls now use AI tools. In March, they launched Avery, a generative AI platform built specifically for member experience. Optum Rx signed more than 800 new client relationships during its 2025 selling cycle. Patrick Conway said on the Q1 call that OptumHealth margins should steadily improve through 2026 and accelerate into 2027. Slight tangent, but the integrated model here — UnitedHealthcare and Optum operating as one closed loop — is what separates UNH from almost every other name in managed care. It’s also exactly what the DOJ is examining most closely.

The DOJ investigation is both criminal and civil. The core allegation: UNH inflated patient diagnoses through in-home nurse assessments to generate higher Medicare Advantage reimbursements from the federal government. A WSJ analysis of Medicare data found those visits triggered an average of $2,735 in added federal payments per visit, with some diagnoses logged without a treating physician involved. As of August 2025, reports indicated the probe had expanded to include Optum Rx billing and how the company compensates its physicians. No charges have been filed. UNH is cooperating, has initiated a third-party review, and points to a prior court-appointed Special Master who reviewed a decade-long civil case and found no wrongdoing. Analysts broadly call it serious but not existential. That is not a clean bill of health — it’s just a calibrated risk assessment.

Worst case: forced restructuring of Optum’s physician business. The exact asset the whole recovery thesis is built on. That outcome is not the base case. But it’s not off the table either.

Then Berkshire filed. On May 15, Berkshire Hathaway disclosed it had fully exited approximately 5.04 million shares of UNH — a position worth roughly $1.6 billion that it had accumulated during the 2025 selloff. The exit came alongside sales of Visa, Mastercard, Amazon, and Domino’s Pizza as part of a broader Q1 portfolio shift under new CEO Greg Abel. Most analysts read it as a Berkshire housekeeping move, not a negative view on UNH fundamentals. The stock still dropped more than 5% in premarket trading the morning the disclosure hit. Perception isn’t always rational. It doesn’t have to be.

Valuation sits near decade lows: roughly 15.5x forward earnings against a 10-year revenue CAGR of around 11%. The dividend yield is near 2.4%, backed by five straight years of double-digit dividend increases. The stock is up approximately 12% year-to-date but still roughly 7% below where it was a year ago. At these multiples, the market is pricing in a meaningful amount of continued uncertainty. The question is whether that discount is appropriate, or whether it’s overdone now that the medical care ratio is showing real improvement.

What matters from here is Q2. If the medical care ratio holds near 83.9% or continues to improve, the Goldman case gets significantly stronger. If elevated utilization trends resurface — and they were cited as a partial offset even in Q1 — the story gets complicated again. The Alegeus Technologies acquisition is expected to close in the second half of 2026 and will be earnings neutral in year one, but it extends UNH’s footprint in consumer-directed healthcare. Watch DOJ developments more than anything else. Even partial clarity on scope — not resolution, just scope — could move this stock more than a full quarter of earnings.

Whether the bottom is actually in or just temporarily visible — that’s the debate nobody has a clean answer to yet.

For informational purposes only. Not financial advice.